Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Proactive management eases side effects of sunitinib treatment in RCC

Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Key clinical point: Adverse events on adjuvant sunitinib were predictable, manageable, and reversible, while decreases in health-related quality of life were not clinically meaningful except for those related to diarrhea and loss of appetite.

Major finding: The EORTC QLQ-C30 global health status/quality of life score favored placebo, with a mean difference in the overall means of –4.76 (P greater than or equal to .0001) that did not exceed the threshold that would indicate clinically meaningful deterioration.

Study details: Analysis of adverse events and patient-reported outcomes for 306 patients treated with sunitinib in the S-TRAC (Sunitinib as Adjuvant Treatment for High-Risk Renal Cell Carcinoma Following Nephrectomy) trial.

Disclosures: Pfizer sponsored the study. The authors reported disclosures related to Pfizer, Bayer, GSK, Roche, BMS, Novartis, Exelixis, AVEO, Merck, Sanofi, Astellas, Celldex, Acerta, Janssen, and others.

Read the article.

Citation:

Staehler M et al. Ann Oncol. 2018 Aug 23. doi : 10.1093/annonc/mdy329.

This Week's Must Reads

Healthcare.gov open enrollment picks up in Week 2, Weekly enrollment snapshot on CMS.gov

Trump administration takes contradictory actions on ACA, A press statement issued on CMS.gov.

Doctors raise concerns about administration's Part B drug plan, A CMS Fact Sheet on the ANPRM International Pricing Index Model for Medicare Part B Drugs

Guideline authors inconsistently disclose conflicts, Combs T et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.4730. Khan R et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.5106

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018